Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report released on Tuesday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of Ayala Pharmaceuticals stock opened at $0.02 on Tuesday. The firm has a fifty day simple moving average of $0.18 and a 200-day simple moving average of $0.47. The stock has a market capitalization of $852,660.00, a price-to-earnings ratio of 0.00 and a beta of 1.56. Ayala Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $1.49.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.